

# David C Wheeler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7537578/publications.pdf>

Version: 2024-02-01

148  
papers

20,759  
citations

34493

54  
h-index

12940

136  
g-index

149  
all docs

149  
docs citations

149  
times ranked

17560  
citing authors

#	ARTICLE	IF	CITATIONS
1	High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. <i>Cardiovascular Research</i> , 2023, 119, 213-220.	1.8	7
2	Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 960-972.	0.4	10
3	Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. <i>American Journal of Kidney Diseases</i> , 2022, 79, 244-256.e1.	2.1	23
4	The burden of subclinical cardiovascular disease in children and young adults with chronic kidney disease and on dialysis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 287-294.	1.4	4
5	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. <i>Kidney International</i> , 2022, 101, 174-184.	2.6	53
6	Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1647-1656.	0.4	48
7	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 24-34.	5.5	40
8	Quã©telet (body mass) index and effects of dapagliflozin in chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 827-837.	2.2	8
9	Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions. <i>Kidney International Reports</i> , 2022, 7, 699-707.	0.4	6
10	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. <i>Diabetes and Metabolism</i> , 2022, 48, 101331.	1.4	5
11	The Kidney Protective Effects of the Sodiumâ€“Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists. <i>Kidney International Reports</i> , 2022, 7, 436-443.	0.4	36
12	Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIAâ€“CKD. <i>Journal of the American Heart Association</i> , 2022, 11, e022003.	1.6	6
13	Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients. <i>JAMA Internal Medicine</i> , 2022, 182, 592.	2.6	28
14	The ASCEND-ND trial: study design and participant characteristics. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2157-2170.	0.4	5
15	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. <i>Diabetologia</i> , 2022, 65, 1085-1097.	2.9	28
16	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. <i>Circulation</i> , 2022, 145, 1460-1470.	1.6	97
17	The Association Between Glycaemic Variability and Progression of Chronic Kidney Disease: a Systematic Review. <i>SN Comprehensive Clinical Medicine</i> , 2022, 4, 1.	0.3	2
18	FC082: Effects of Dapagliflozin in Patients with Chronic Kidney Disease According to Background Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dose. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0

#	ARTICLE	IF	CITATIONS
19	FC 122: Effects of Canagliflozin on Cardiovascular and Kidney Events in Patients With Chronic Kidney Disease With and Without Peripheral Vascular Disease: Integrated Analysis From the Canvas Program and Credence Trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
20	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1888.	3.8	103
21	Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-12.	1.0	3
22	Routine serum biomarkers, but not dual-energy X-ray absorptiometry, correlate with cortical bone mineral density in children and young adults with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1872-1881.	0.4	15
23	“Epigenome-wide methylation profile of chronic kidney disease-derived arterial DNA uncovers novel pathways in disease-associated cardiovascular pathology.” <i>Epigenetics</i> , 2021, 16, 718-728.	1.3	10
24	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021, 143, 438-448.	1.6	85
25	Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. <i>American Journal of Kidney Diseases</i> , 2021, 77, 23-34.e1.	2.1	38
26	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021, 99, 999-1009.	2.6	93
27	The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals. <i>Kidney International</i> , 2021, 99, 551-554.	2.6	2
28	Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 22-31.	5.5	287
29	The Prescription of Intradialytic Exercise to Improve Quality of Life in Patients with Chronic Kidney Disease Trial: Study Design and Baseline Data for a Multicentre Randomized Controlled Trial. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1345-1355.	1.4	10
30	Perspectives on blood pressure by patients on haemo- and peritoneal dialysis. <i>Nephrology</i> , 2021, 26, 62-69.	0.7	8
31	Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. <i>European Heart Journal</i> , 2021, 42, 1216-1227.	1.0	75
32	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <i>American Heart Journal</i> , 2021, 233, 141-148.	1.2	30
33	Methods and rationale of the DISCOVER CKD global observational study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1570-1578.	1.4	11
34	Understanding and Overcoming the Challenges Related to Cardiovascular Trials Involving Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1435-1444.	2.2	6
35	MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	1
36	Time-dependent lipid profile inversely associates with mortality in hemodialysis patients “ independent of inflammation/malnutrition. <i>Journal of Internal Medicine</i> , 2021, 290, 910-921.	2.7	8

#	ARTICLE	IF	CITATIONS
37	FC 089EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSES FROM THE CANVAS PROGRAM AND CREDENCE TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
38	MO516A STRUCTURED EXPERT ELICITATION TO INFORM AND VALIDATE MORTALITY EXTRAPOLATIONS FOR A COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	1
39	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021, 44, 1894-1897.	4.3	47
40	Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-52.	1.3	19
41	The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 1447-1455.	0.7	14
42	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. <i>Kidney International</i> , 2021, 100, 215-224.	2.6	182
43	Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. <i>JACC: Heart Failure</i> , 2021, 9, 518-527.	1.9	9
44	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2352-2361.	3.0	88
45	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021, 42, 4891-4901.	1.0	80
46	Randomized Trial of Prescription of Intradialytic Exercise to Improve Quality of Life in Patients Receiving Hemodialysis. <i>Kidney International Reports</i> , 2021, 6, 2159-2170.	0.4	22
47	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 807-820.	1.9	49
48	Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. <i>Kidney360</i> , 2021, 2, 10.34067/KID.0004272021.	0.9	7
49	Standardised Outcomes in Nephrology – Chronic Kidney Disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy. <i>Trials</i> , 2021, 22, 612.	0.7	12
50	Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 743-754.	5.5	87
51	Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 755-766.	5.5	86
52	Survival on four compared with three times per week haemodialysis in high ultrafiltration patients: an observational study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 665-672.	1.4	5
53	Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 385, 2313-2324.	13.9	108
54	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2021, 52, 827-836.	1.4	15

#	ARTICLE	IF	CITATIONS
55	Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 385, 2325-2335.	13.9	112
56	Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 478-487.	0.4	19
57	Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1570-1576.	0.4	11
58	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 42-61.	2.6	260
59	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	1.0	2,811
60	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <math>\leq 7\%</math>. <i>Circulation</i> , 2020, 141, 407-410.	1.6	95
61	Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes. <i>Journal of Nephrology</i> , 2020, 33, 803-816.	0.9	8
62	Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus. <i>American Journal of Nephrology</i> , 2020, 51, 74-82.	1.4	31
63	Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 903-914.	5.5	73
64	Correction of anemia by dapagliflozin in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107729.	1.2	24
65	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020, 98, 849-859.	2.6	65
66	Dapagliflozin in Patients with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 383, 1436-1446.	13.9	2,523
67	Effects of Canagliflozin in Patients with Baseline eGFR <math>\leq 30</math> ml/min per 1.73 m <sup>2</sup> . <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1705-1714.	2.2	87
68	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. <i>Kidney International</i> , 2020, 98, 1407-1418.	2.6	8
69	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. <i>Kidney International</i> , 2020, 98, 1108-1119.	2.6	26
70	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1700-1711.	0.4	107
71	HEROIC: a 5-year observational cohort study aimed at identifying novel factors that drive diabetic kidney disease: rationale and study protocol. <i>BMJ Open</i> , 2020, 10, e033923.	0.8	1
72	Estradiol and mortality in women with end-stage kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1965-1972.	0.4	8

#	ARTICLE	IF	CITATIONS
73	MO016MYOCARDIAL INFARCTION IN THE PIVOTAL STUDY OF IV IRON IN HAEMODIALYSIS: A PRE-SPECIFIED SECONDARY ANALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
74	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1128-1139.	3.0	106
75	P1371HEART FAILURE HOSPITALISATIONS IN THE PIVOTAL TRIAL OF IV IRON IN HAEMODIALYSIS PATIENTS: A PRE-SPECIFIED SECONDARY ANALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
76	Hospitalization and mortality following non-attendance for hemodialysis according to dialysis day of the week: a European cohort study. <i>BMC Nephrology</i> , 2020, 21, 218.	0.8	9
77	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2020, 76, 109-120.	2.1	10
78	P0816CLINICAL CHARACTERISTICS AND EGFR AND UACR DISTRIBUTION ACCORDING TO THE 2012 KDIGO CKD CLASSIFICATION: A REPORT FROM THE US DISCOVER CKD COHORT. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
79	Patient and Caregiver Perspectives on Terms Used to Describe Kidney Health. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 937-948.	2.2	47
80	MO015HAEMODIALYSIS VASCULAR ACCESS THROMBOSIS: AN ANALYSIS OF EVENTS FROM THE PROACTIVE IV IRON THERAPY IN HAEMODIALYSIS PATIENTS (PIVOTAL) TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
81	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 274-282.	0.4	168
82	Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1761-1769.	0.4	5
83	Patient and Caregiver Priorities for Outcomes in CKD: A Multinational Nominal Group Technique Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 679-689.	2.1	56
84	Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1433-1444.	2.2	40
85	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019, 140, 739-750.	1.6	211
86	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 845-854.	5.5	595
87	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 836-849.	2.6	80
88	2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Diseaseâ€“Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report. <i>Kidney International Reports</i> , 2019, 4, 1523-1537.	0.4	29
89	Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 429-441.	5.5	137
90	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	2.6	232

#	ARTICLE	IF	CITATIONS
91	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019, 380, 2295-2306.	13.9	3,760
92	Development of an International Standard Set of Value-Based Outcome Measures for Patients With Chronic Kidney Disease: A Report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group. <i>American Journal of Kidney Diseases</i> , 2019, 73, 372-384.	2.1	90
93	New pharmacological strategies for protecting kidney function in type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 397-412.	5.5	64
94	Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. <i>New England Journal of Medicine</i> , 2019, 380, 447-458.	13.9	321
95	CHRONIC KIDNEY DISEASE AND ARRHYTHMIAS: CONCLUSIONS FROM A KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO) CONTROVERSIES CONFERENCE. <i>Nephrology (Saint-Petersburg)</i> , 2019, 23, 18-40.	0.1	5
96	Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2018, 72, 62-74.	2.1	39
97	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>European Heart Journal</i> , 2018, 39, 2314-2325.	1.0	186
98	Risk Factors for Prognosis in Patients With Severely Decreased GFR. <i>Kidney International Reports</i> , 2018, 3, 625-637.	0.4	35
99	Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3-4 chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 2005-2011.	0.4	72
100	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. <i>Kidney International</i> , 2018, 93, 1000-1007.	2.6	32
101	FP634HIGH ALL CAUSE AND CVD MORTALITY IN AN INCIDENT COHORT OF HEMODIALYSIS PATIENTS WITH LOW SERUM ALBUMIN AND INFLAMMATION. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i257-i257.	0.4	0
102	FP366OUTCOMES OF PEOPLE WITH CHRONIC KIDNEY DISEASE STAGES 3-5 MANAGED IN PRIMARY CARE IN THE UK - FINDINGS FROM THE NATIONAL CKD AUDIT. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i155-i155.	0.4	0
103	FP657STAKEHOLDER PRIORITIES FOR CARDIOVASCULAR OUTCOMES IN HEMODIALYSIS TRIALS: AN INTERNATIONAL SURVEY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i266-i267.	0.4	1
104	Sa0066THE VARIATION IN HOSPITALISATION AND MORTALITY FOLLOWING NON-ATTENDANCE FOR HAEMODIALYSIS ACCORDING TO DIALYSIS DAY OF THE WEEK IN A EUROPEAN COHORT: FURTHER EVIDENCE OF HARM FROM THE TWO-DAY BREAK IN THREE TIMES A WEEK HAEMODIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i344-i344.	0.4	1
105	Clinicians' and researchers' perspectives on establishing and implementing core outcomes in haemodialysis: semistructured interview study. <i>BMJ Open</i> , 2018, 8, e021198.	0.8	9
106	Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. <i>American Journal of Nephrology</i> , 2018, 48, 260-268.	1.4	30
107	Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2015-2027.	3.0	140
108	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 1505-1514.	1.6	145

#	ARTICLE	IF	CITATIONS
109	Nephrologistsâ€™ Perspectives on Defining and Applying Patient-Centered Outcomes in Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 454-466.	2.2	40
110	Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. <i>American Journal of Kidney Diseases</i> , 2017, 70, 464-475.	2.1	218
111	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet</i> , The, 2017, 390, 1888-1917.	6.3	662
112	Accounting for overdispersion when determining primary care outliers for the identification of chronic kidney disease: learning from the National Chronic Kidney Disease Audit. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, ii151-ii158.	0.4	5
113	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2017, 69, 314-322.	1.3	30
114	Reducing major risk factors for chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 71-87.	4.6	155
115	Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. <i>Kidney International Supplements</i> , 2017, 7, 122-129.	4.6	106
116	Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 432.	3.8	376
117	The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease. <i>Kidney International</i> , 2017, 92, 809-815.	2.6	81
118	Sex Hormone Status in Women With Chronic Kidney Disease: Survey of Nephrologistsâ€™ and Renal Allied Health Care Providersâ€™ Perceptions. <i>Canadian Journal of Kidney Health and Disease</i> , 2017, 4, 205435811773453.	0.6	20
119	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017, 46, 462-472.	1.4	194
120	The VITAH Trialâ€”Vitamin D Supplementation and Cardiac Autonomic Tone in Patients with End-Stage Kidney Disease on Hemodialysis: A Blinded, Randomized Controlled Trial. <i>Nutrients</i> , 2016, 8, 608.	1.7	7
121	MP313 IDENTIFYING OUTLYING PRACTICES IN PREVALENCE OF CKD IN PRIMARY CARE. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i443-i443.	0.4	0
122	Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney Transplantation. <i>Transplantation Direct</i> , 2016, 2, e79.	0.8	30
123	Standardised Outcomes in Nephrologyâ€”Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease. <i>Trials</i> , 2016, 17, 401.	0.7	41
124	Statins for hemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D Study. <i>Kidney International</i> , 2016, 89, 1189-1191.	2.6	6
125	Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. <i>American Journal of Kidney Diseases</i> , 2016, 68, 444-454.	2.1	232
126	Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 738-747.	0.9	17



#	ARTICLE	IF	CITATIONS
127	Standardised outcomes in nephrology – Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. <i>Trials</i> , 2015, 16, 364.	0.7	67
128	A Fine Balance: Developing Clinical Practice Guidelines in Areas Where Evidence is Lacking. <i>Seminars in Dialysis</i> , 2015, 28, 654-656.	0.7	5
129	Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. <i>Lancet</i> , The, 2015, 385, 2047-2056.	6.3	321
130	The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 791-799.	2.2	75
131	Vitamin D Supplementation Is Associated With Stabilization of Cardiac Autonomic Tone in IgA Nephropathy. <i>Hypertension</i> , 2015, 66, e4-6.	1.3	8
132	Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. <i>Circulation</i> , 2015, 132, 27-39.	1.6	259
133	High cardiovascular event rates occur within the first weeks of starting hemodialysis. <i>Kidney International</i> , 2015, 88, 1117-1125.	2.6	96
134	Acute Stroke Thrombolysis in End-Stage Renal Disease: A National Survey of Nephrologist Opinion. <i>Nephron Clinical Practice</i> , 2014, 124, 167-172.	2.3	10
135	Inflammatory stress reduces the effectiveness of statins in the kidney by disrupting HMGCoA reductase feedback regulation. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1864-1878.	0.4	10
136	Is Intensive Blood Pressure Lowering Justifiable in CKD?. <i>American Journal of Kidney Diseases</i> , 2014, 63, 903-905.	2.1	1
137	Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?. <i>Kidney International</i> , 2013, 83, 377-383.	2.6	155
138	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet</i> , The, 2011, 377, 2181-2192.	6.3	2,087
139	An Epidemiological Study of Hemodialysis Patients Based on the European Fresenius Medical Care Hemodialysis Network: Results of the ARO Study. <i>Nephron Clinical Practice</i> , 2011, 118, c143-c154.	2.3	23
140	The Jupiter trial – new territory for statins?*. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2036-2037.	0.4	2
141	Mesangial matrix-activated mononuclear cells express functional scavenger receptors and accumulate intracellular lipid. <i>International Journal of Experimental Pathology</i> , 2008, 85, A26-A27.	0.6	0
142	New-onset diabetes after transplantation. <i>British Journal of Hospital Medicine (London, England:)</i> Tj ETQq0 0 0 rgBT, Overlock 10 Tf 50 4	0.2	4
143	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Misleading Associations between Cholesterol and Vascular Outcomes in Dialysis Patients: The Need for Randomized Trials. <i>Seminars in Dialysis</i> , 2007, 20, 498-503.	0.7	23
144	Which issues should trials address in hemodialysis?. <i>Hemodialysis International</i> , 2007, 11, S44-S47.	0.4	0

#	ARTICLE	IF	CITATIONS
145	NDT contributes to a collection of 100 seminal papers published by Oxford University Press. Nephrology Dialysis Transplantation, 2006, 21, 2047-2048.	0.4	0
146	Cardiovascular risk factors in predialysis patients: Baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study. Kidney International, 2003, 63, S201-S203.	2.6	58
147	Synthesis of 1,25-Dihydroxyvitamin D3 by Human Endothelial Cells Is Regulated by Inflammatory Cytokines. Journal of the American Society of Nephrology: JASN, 2002, 13, 621-629.	3.0	285
148	Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins. Journal of Nephrology, 2001, 14 Suppl 4, S70-5.	0.9	4